RenovoRx, Inc.(RNXT)

Biotechnology · Mountain View, CA

$1.40-0.07 (-5.10%)

Delayed quote: Oct 6, 2026, 2:15 PM EDT

EV/EBIT Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBIT ratio is N/A as of 2026-10-06T18:18:42.681Z.

Stored calculation inputs

Calculation as of: 2026-10-06T18:18:42.681Z.

Quote observation: 2026-10-06T18:15:07.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 62,853,022
Total debt · period ending 2026-06-30: 259,000
Cash · period ending 2026-06-30: 9,479,000
TTM operating income · period ending 2026-06-30: -13,398,000

FMP input reference: f2bd7b982a7c38b7b5dde5784864fe9761ce9be9b841b4296251164aedb1f89c

EV/EBITDA|EV/Sales|Operating Income|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

RNXT EV/EBIT Ratio Metrics

EV/EBIT RATIO

N/A

RNXT Competitors' EV/EBIT Ratio

RNXT

RenovoRx, Inc.

Current

Market Cap

$62.85M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PLRX

Pliant Therapeutics, Inc.

vs RNXT

Market Cap

$62.85M

EV/EBIT Ratio

N/A

TTM Avg

31.50x

3Y Avg

31.50x

5Y Avg

31.50x

ALPS

Alps Group Inc

vs RNXT

Market Cap

$63.23M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

HRTX

Heron Therapeutics, Inc.

vs RNXT

Market Cap

$63.41M

EV/EBIT Ratio

N/A

TTM Avg

237.48x

3Y Avg

237.48x

5Y Avg

237.48x

INCR

InterCure Ltd.

vs RNXT

Market Cap

$63.64M

EV/EBIT Ratio

N/A

TTM Avg

9.73x

3Y Avg

23.03x

5Y Avg

21.55x

GOSS

Gossamer Bio, Inc.

vs RNXT

Market Cap

$64.83M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

KLRS

Kalaris Therapeutics Inc

vs RNXT

Market Cap

$61.12M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GUTS

Fractyl Health, Inc.

vs RNXT

Market Cap

$61.67M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

XLO

Xilio Therapeutics, Inc.

vs RNXT

Market Cap

$60.89M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ONCY

Oncolytics Biotech Inc.

vs RNXT

Market Cap

$60.02M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
RenovoRx, Inc. (RNXT)	$62.85M	N/A	N/A	N/A	N/A
Pliant Therapeutics, Inc. (PLRX)vs ›	$62.85M	N/A	31.50x	31.50x	31.50x
Alps Group Inc (ALPS)vs ›	$63.23M	N/A	N/A	N/A	N/A
Heron Therapeutics, Inc. (HRTX)vs ›	$63.41M	N/A	237.48x	237.48x	237.48x
InterCure Ltd. (INCR)vs ›	$63.64M	N/A	9.73x	23.03x	21.55x
Gossamer Bio, Inc. (GOSS)vs ›	$64.83M	N/A	N/A	N/A	N/A
Kalaris Therapeutics Inc (KLRS)vs ›	$61.12M	N/A	N/A	N/A	N/A
Fractyl Health, Inc. (GUTS)vs ›	$61.67M	N/A	N/A	N/A	N/A
Xilio Therapeutics, Inc. (XLO)vs ›	$60.89M	N/A	N/A	N/A	N/A
Oncolytics Biotech Inc. (ONCY)vs ›	$60.02M	N/A	N/A	N/A	N/A

EV/EBIT Ratio Formula & Definition

EV/EBIT = Enterprise Value / EBIT (TTM)

Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EV/EBIT Ratio: N/A

RNXT EV/EBIT Ratio Metrics

RNXT Competitors' EV/EBIT Ratio

EV/EBIT Ratio Formula & Definition

Related Metrics